One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences &#8805;10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.

Verburgh, Myrthe L; Wit, Ferdinand W N M; Boyd, Anders; Verboeket, Sebastiaan O; Reiss, Peter; van der Valk, Marc

One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.

Verburgh, Myrthe L; Wit, Ferdinand W N M; Boyd, Anders; Verboeket, Sebastiaan O; Reiss, Peter; van der Valk, Marc.

Affiliation

Verburgh ML; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Wit FWNM; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Boyd A; HIV Monitoring Foundation, Amsterdam, The Netherlands.
Verboeket SO; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Reiss P; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
van der Valk M; Infectious Diseases, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Open Forum Infect Dis ; 9(7): ofac291, 2022 Jul.

Article de En | MEDLINE | ID: mdl-35873291

Mots clés

antiretroviral therapy switch; integrase strand transfer inhibitor; metabolic parameters; tenofovir alafenamide; weight gain

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Open Forum Infect Dis Année: 2022 Type de document: Article Pays d'affiliation: Pays-Bas

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google